A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis of 3 to 5 years after diagnosis. But the new drug, nerandomilast (Boehringer Ingelheim), could revolutionize the treatment of the disease after several failures of all potential new drugs tested for this disease in the last decade that have failed in phase 2 or phase 3 studies.
This article was originally published on MedicalXpress.com
